ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2843

Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects

Victoria Werth1, David Pearson 2, Joyce Okawa 2, Rui Feng 3, Josef Concha 2, Basil Patel 2, Emily Hejazi 2, Scott Constantine 4, Nancy Dgetluck 4 and Barbara White 4, 1Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, 2Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, 4Corbus Pharmaceuticals, Norwood, MA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Amyopathic dermatomyositis, clinical trials, cutaneous manifestations and patient outcomes, dermatomyositis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes. Lenabasum had acceptable safety and tolerability and improved efficacy outcomes in the initial 16-week double-blinded, randomized, placebo-controlled Part A of Phase 2 trial JBT101-DM-001 (NCT02466243) in classic or amyopathic dermatomyositis (DM) subjects with refractory skin disease and minimal or no active muscle involvement at the time of enrollment.

Methods: To provide long-term safety and efficacy data in DM subjects in study JBT101-DM-001, subjects who completed Part A were eligible to receive oral lenabasum 20 mg BID in an open-label extension (OLE) of that study that assessed safety and efficacy at 4 weeks, then every 8 weeks.

Results: 20/22 (91%) eligible subjects received lenabasum in the OLE.  Seventeen (85%) subjects were on stable baseline immunosuppressive drugs.  At the time of data cut-off, 18 (90%) subjects who enrolled in the OLE had entered the second year of the OLE, and all 18 had completed Week 68.

Twenty/20 (100%) of subjects experienced at least 1 AE, with 65 total AEs occurring among the subjects during the OLE to date.  The majority of AEs were mild (n = 16, 80%), and only 1 subject had an AE probably or definitely-related to lenabasum (mild fatigue).  Only 1 subject had a severe AE (fatigue) and that AE was considered unrelated to lenabasum.  AEs occurring in 3 (15%) subjects were dermatomyositis worsening (2 mild, 1 moderate), dizziness (all mild), fatigue (2 mild, 1 severe), nasopharyngitis (all mild). AEs occurring in 2 (10%) subjects were headache, herpes zoster, nausea, sinusitis, upper respiratory tract infection, and urinary tract infection – all were mild except 1 AE of sinusitis was moderate.  No serious AEs have been reported in this study to date.  

Improvement was seen in multiple physician- and patient-reported efficacy outcomes; selected outcomes are presented in Figure 1. Mean (SE) changes from study start at Week 68 in the OLE were: CDASI activity score = -21.8 (2.26), Patient Skin Activity VAS  = -3.0 (0.75); Skindex-29 Symptoms Domain  = -28.0 (SD); 5D Itch Score = -3.7 (SD); Physician Overall Disease VAS = -3.0 (SD); and Promis-29 Pain Interference = -4.5 (SD). Improvements were seen in other patient- and physician-reported efficacy outcomes. During the OLE, 2 subjects reduced mycophenolate, 2 were switched from methotrexate to mycophenolate, 1 started methotrexate, and 1 had a burst and taper of steroids.

Conclusion: To date, lenabasum treatment has been safe and well tolerated in the Phase 2 study JBT101-DM-001, with no serious AEs or study discontinuations related to lenabasum.  The CDASI activity score and multiple other physician and patient-reported outcomes improved, although limitations of attributing efficacy to lenabasum in the setting of open-label dosing is acknowledged.  These data support further testing of lenabasum for the treatment of DM, and a Phase 3 study of lenabasum in DM has started.


Disclosure: V. Werth, Biogen, 2, 5, Corbus Pharmaceuticals, 2, 9, University of Pennsylvania, 9; D. Pearson, None; J. Okawa, None; R. Feng, None; J. Concha, None; B. Patel, None; E. Hejazi, None; S. Constantine, Corbus Pharmaceuticals, 1, 3, 4; N. Dgetluck, Corbus Pharmaceuticals, 3, 4; B. White, Corbus Pharmaceuticals, 1, 3, 4, 6.

To cite this abstract in AMA style:

Werth V, Pearson D, Okawa J, Feng R, Concha J, Patel B, Hejazi E, Constantine S, Dgetluck N, White B. Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/safety-and-efficacy-of-lenabasum-at-week-68-in-an-open-label-extension-of-a-phase-2-study-of-lenabasum-in-refractory-skin-predominant-dermatomyositis-dm-subjects/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-lenabasum-at-week-68-in-an-open-label-extension-of-a-phase-2-study-of-lenabasum-in-refractory-skin-predominant-dermatomyositis-dm-subjects/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences